Next Article in Journal
Non-Inherited Maternal Antigens Identify Acceptable HLA Mismatches: A New Policy for the Hellenic Cord Blood Bank
Previous Article in Journal
Endometrial Stem Cells in Farm Animals: Potential Role in Uterine Physiology and Pathology
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Bioengineering 2018, 5(4), 76; https://doi.org/10.3390/bioengineering5040076

Integrin-Mediated Delivery of Drugs and Nucleic Acids for Anti-Angiogenic Cancer Therapy: Current Landscape and Remaining Challenges

1
Division of Lipid Science and Technology, CSIR-Indian Institute of Chemical Technology, Uppal Road, Tarnaka, Hyderabad 500007, India
2
Chemical Biology Laboratory, National Cancer Institute, 376 Boyles St, Frederick, MD 21702, USA
Received: 8 August 2018 / Revised: 12 September 2018 / Accepted: 16 September 2018 / Published: 20 September 2018
(This article belongs to the Special Issue Targeted Drug Delivery)
Full-Text   |   PDF [3200 KB, uploaded 20 September 2018]   |  

Abstract

Angiogenesis, sprouting of new blood vessels from pre-existing vasculatures, plays a critical role in regulating tumor growth. Binding interactions between integrin, a heterodimeric transmembrane glycoprotein receptor, and its extracellular matrix (ECM) protein ligands govern the angiogenic potential of tumor endothelial cells. Integrin receptors are attractive targets in cancer therapy due to their overexpression on tumor endothelial cells, but not on quiescent blood vessels. These receptors are finding increasing applications in anti-angiogenic therapy via targeted delivery of chemotherapeutic drugs and nucleic acids to tumor vasculatures. The current article attempts to provide a retrospective account of the past developments, highlight important contemporary contributions and unresolved set-backs of this emerging field. View Full-Text
Keywords: Integrin; drug delivery; angiogenesis; anti-angiogenic therapy; siRNA; tumor-homing peptides; combination delivery of drug and nucleic acids Integrin; drug delivery; angiogenesis; anti-angiogenic therapy; siRNA; tumor-homing peptides; combination delivery of drug and nucleic acids
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Majumder, P. Integrin-Mediated Delivery of Drugs and Nucleic Acids for Anti-Angiogenic Cancer Therapy: Current Landscape and Remaining Challenges. Bioengineering 2018, 5, 76.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Bioengineering EISSN 2306-5354 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top